Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Alemtuzumab in Combination With CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma

NCT00930605 is registered in ClinicalTrials.gov with King Chulalongkorn Memorial Hospital as lead sponsor.

NCT NCT00930605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00930605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Alemtuzumab in Combination With CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma
Lead sponsor
King Chulalongkorn Memorial Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
July 31, 2008
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma